Pfizer Inc (New York, NY) received approval from U.S. regulators for its acquisition of Hospira Inc (Lake Forest, IL), pending the divestiture of some sterile injectable drugs. Pfizer has agreed to divest four U.S. sterile injectable assets: Acetylcysteine, Clindamycin, Voriconazole, and Melphalan. The deal is now expected to close in early September 2015.
Market Pulse transactions shown herein are provided as a matter of public record. These transactions have been compiled from press releases, corporate announcements and other public sources to provide an overview of acquisition and merger activities within the healthcare and life sciences sectors.